{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:34:28Z","timestamp":1794407668294,"version":"4.9.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s40265-021-01482-5","type":"journal-article","created":{"date-parts":[[2021,3,11]],"date-time":"2021-03-11T10:04:31Z","timestamp":1615457071000},"page":"503-507","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":135,"title":["Orelabrutinib: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,11]]},"reference":[{"issue":"2","key":"1482_CR1","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/sji.12069","volume":"78","author":"L Vargas","year":"2013","unstructured":"Vargas L, Hamasy A, Nore BF, et al. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases. Scand J Immunol. 2013;78(2):130\u20139.","journal-title":"Scand J Immunol."},{"key":"1482_CR2","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2147\/ITT.S240874","volume":"9","author":"A Lorenzo-Vizcaya","year":"2020","unstructured":"Lorenzo-Vizcaya A, Fasano S, Isenberg DA. Bruton\u2019s tyrosine kinase inhibitors: a new therapeutic target for the treatment of SLE? Immunotargets Ther. 2020;9:105\u201310.","journal-title":"Immunotargets Ther."},{"issue":"1","key":"1482_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","volume":"17","author":"S Pal Singh","year":"2018","unstructured":"Pal Singh S, Dammeijer F, Hendriks RW. Role of Bruton\u2019s tyrosine kinase in B cells and malignancies. Mol Cancer. 2018;17(1):57.","journal-title":"Mol Cancer."},{"issue":"1","key":"1482_CR4","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41573-020-0082-8","volume":"20","author":"AA Zarrin","year":"2021","unstructured":"Zarrin AA, Bao K, Lupardus P, et al. Kinase inhibition in autoimmunity and inflammation. Nat Rev Drug Discov. 2021;20(1):39\u201363.","journal-title":"Nat Rev Drug Discov."},{"issue":"7 Spec No.","key":"1482_CR5","first-page":"SP226-SP7","volume":"26","author":"ML Shaw","year":"2020","unstructured":"Shaw ML. Second-generation BTK inhibitors hit the treatment bullseye with fewer off-target effects. Am J Manag Care. 2020;26(7 Spec No.):SP226\u20137.","journal-title":"Am J Manag Care."},{"key":"1482_CR6","unstructured":"NMPA China. Orelabrutinib tablets. 2021. http:\/\/app1.nmpa.gov.cn\/data_nmpa\/face3\/dir.html. Accessed 27 Jan 2021."},{"key":"1482_CR7","volume-title":"Orelabrutinib: Chinese prescribing information","author":"InnoCare Pharma Ltd","year":"2021","unstructured":"InnoCare Pharma Ltd. Orelabrutinib: Chinese prescribing information. Beijing: Innocare Pharma Ltd.; 2021."},{"key":"1482_CR8","doi-asserted-by":"crossref","unstructured":"Zhang B, Zhao R, Liang R, et al. Orelabrutinib, a potent and selective Bruton's tyrosine kinase inhibitor with superior safety profile and excellent PK\/PD properties [abstract no. CT132]. In: Proceedings American Association for Cancer Research Annual Meeting. 2020.","DOI":"10.1158\/1538-7445.AM2020-CT132"},{"key":"1482_CR9","doi-asserted-by":"crossref","unstructured":"Song Y, Liu L, Zhang M, et al. Safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study [abstract no. 755]. Blood 2019;134(Suppl. 1).","DOI":"10.1182\/blood-2019-126305"},{"issue":"Suppl. 1","key":"1482_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood-2020-141781","volume":"136","author":"Y Song","year":"2020","unstructured":"Song Y, Song Y, Liu L, et al. Long-term safety and efficacy of orelabrutinib monotherapy in Chinese patients with relapsed or refractory mantle cell lymphoma: a multicenter, open-label, phase II study [abstract]. Blood. 2020;136(Suppl. 1):1.","journal-title":"Blood"},{"key":"1482_CR11","doi-asserted-by":"crossref","unstructured":"Xu W, Song Y, Li Z, et al. Safety, tolerability and efficacy of orelabrutinib, once a day, to treat Chinese patients with relapsed or refractory chronic lymphocytic leukemia\/small cell leukemia [abstract]. Blood. 2019;134(Suppl. 1):4319.","DOI":"10.1182\/blood-2019-123331"},{"issue":"Suppl. 1","key":"1482_CR12","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1182\/blood-2020-134531","volume":"136","author":"W Xu","year":"2020","unstructured":"Xu W, Song Y, Wang T, et al. Updated results from the phase II study of orelabrutinib monotherapy in Chinese patients with relapsed or refractory chronic lymphocytic leukemia\/ small cell leukemia [abstract]. Blood. 2020;136(Suppl. 1):26\u20137.","journal-title":"Blood"},{"issue":"Suppl. 1","key":"1482_CR13","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1182\/blood-2020-140172","volume":"136","author":"Y Song","year":"2020","unstructured":"Song Y, Xu W, Liu L, et al. Pooled analysis of safety data from clinical trials of orelabrutinib monotherapy in hematologic malignancies [abstract]. Blood. 2020;136(Suppl. 1):43.","journal-title":"Blood"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01482-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-021-01482-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01482-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T14:33:20Z","timestamp":1616250800000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-021-01482-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["1482"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01482-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"16 February 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, consent to participate, consent to publish, availability of data and material, code availability"}}]}}